Sarepta Therapeutics Inc. announced the advancement of its siRNA collaboration, specifically highlighting progress in the Phase 1/2 clinical study of SRP-1003, an investigational RNA interference therapeutic aimed at treating type 1 myotonic dystrophy $(DM1.AU)$. The company reported that a $100 million milestone payment obligation was triggered after achieving a predetermined enrollment target in the study. Sarepta plans to release preliminary data from this study in the second half of 2025. Additionally, Sarepta has sold a portion of its common stock holdings in Arrowhead Pharmaceuticals, Inc. to generate at least $174 million in gross proceeds and has made arrangements to transfer shares to Arrowhead to fulfill part of the milestone payment. The company emphasizes that these financial moves are strategic and do not reflect a change in their belief in the potential of siRNA technology.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。